Is ALNY or ALZN more undervalued in 2026?

CirclFi compares Alnylam Pharmaceuticals, Inc. (ALNY) and Alzamend Neuro, Inc. (ALZN) using 13 institutional-grade valuation models. ALNY has a Quality of Company score of 9.7/10 while ALZN scores 4.1/10.

Which is a better buy — ALNY or ALZN?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ALNY and ALZN valuations compare?

ALNY at $305.06 and ALZN at $1.15 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ALNY vs ALZN Valuation Comparison 2026 — Intrinsic Value Analysis

ALNY

Biotechnology

Alnylam Pharmaceuticals, Inc.

Quality

9.7

out of 10

Value Trap

SAFE

Price

$305.06

Last close

Models

11/13

Active

ALZN

Biotechnology

Alzamend Neuro, Inc.

Quality

4.1

out of 10

Value Trap

SAFE

Price

$1.15

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	ALNY Fair Value	ALNY Upside	ALZN Fair Value	ALZN Upside
Bayesian DCF	Intrinsic	$29.56	-90.3%	$0.70	-39.3%
Earnings Power Value	Intrinsic	$33.29	-89.1%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	—	—	$0.05	-95.4%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ALNY vs ALZN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ALNY vs ALZN — Which Stock Is More Undervalued?

ALNY scores higher with a 9.7/10 quality rating vs ALZN's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Alnylam Pharmaceuticals, Inc. (ALNY) and Alzamend Neuro, Inc. (ALZN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ALNY currently trades at $305.06 with a QOC of 9.7/10, while ALZN trades at $1.15 with a QOC of 4.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).